[11C]BMT-136088

Drug Profile

[11C]BMT-136088

Alternative Names: BMS 986202 companion diagnostic - Bristol-Myers Squibb

Latest Information Update: 06 Mar 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibrosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 01 Jan 2015 Bristol-Myers Squibb completes phase I trials in Idiopathic pulmonary fibrosis and Fibrosis (Diagnosis) (NCT02017730)
  • 01 Jan 2014 Phase-I trials in Idiopathic pulmonary fibrosis (Diagnosis) in USA (IV)
  • 01 Jan 2014 Phase-I trials in Fibrosis (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top